Statement regarding latest media publications
In reference to information published in media, especially in “Transakcja w USA zagrożona?” (The U.S. transaction threatened?) and “Medicalgorithmics ma problem w USA” (Medicalgorithmics has a problem in the U.S.) published in Gazeta Giełdy Parkiet No 50 (5977) on March 2, 2016, the Board of Medicalgorithmics S.A. informs that with respect to the purchase of 75% shares in Medi-Lynx the Company fulfilled all its information obligations, and the information about court proceedings in the cited articles does not currently influence the transaction and, in the Company’s opinion, does not meet the publication criteria that must be satisfied to fulfil information obligations and apply best market practice.
In the Board’s opinion, AMI/Spectocor actions are aimed at delaying and obstructing the transaction, putting pressure on the Company and influencing its strategic decisions. Moreover, it seems that these actions are aimed to mislead Medicalgorithmics S.A. Partners, Shareholders and Stakeholders.